Evidence map›Paper›PMID 32224991›Full record

ArticleMicroorganisms2020

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for

Jean A Bernatchez, Emily Chen, Mitchell V Hull, Case W McNamara, James H McKerrow, Jair L Siqueira-Neto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Revisiting cysteine protease function inMicrobiology spectrum · 2026
    Article
  3. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Challenges in Chagas Disease Drug Development.Molecules (Basel, Switzerland) · 2020
    Review
  13. Identification of Inhibitors toInternational journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jean A BernatchezSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
Emily ChenCalibr, a division of The Scripps Research Institute, La Jolla, CA 92037, USA.
Mitchell V HullCalibr, a division of The Scripps Research Institute, La Jolla, CA 92037, USA.
Case W McNamaraCalibr, a division of The Scripps Research Institute, La Jolla, CA 92037, USA.
James H McKerrowSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
Jair L Siqueira-NetoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA.

Funding

Bill and Melinda Gates Foundation OPP1107194
6 · The paper itself

Abstract

Chagas disease, caused by the kinetoplastid parasite

Indexed as

antiparasiticsdrug repurposinghigh-throughput screeningTrypanosoma cruzi

Identifiers

PMID32224991
PMCPMC7232187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.